Patient Characteristics
| . | ALL . | IDM/HDM-150 . | MP-151 . |
|---|---|---|---|
| No. patients | 70 | 32 | 38 |
| Age | |||
| Median | 61 | 52 | 67 |
| Range | 34-86 | 35-65 | 35-85 |
| Sex (male:female) | 44:26 | 18:14 | 26:12 |
| M-component | |||
| IgG | 44 | 22 | 22 |
| IgA | 16 | 7 | 9 |
| IgD | 1 | 1 | |
| LCD | 9 | 3 | 6 |
| k:λ | 41:29 | 19:13 | 22:16 |
| Stage: | |||
| II-A | 13 | 5 | 8 |
| III-A | 50 | 25 | 25 |
| III-B | 7 | 2 | 5 |
| Performance status (ECOG) | |||
| 0 | 9 | 4 | 5 |
| 1 | 22 | 9 | 13 |
| 2 | 21 | 9 | 12 |
| 3 | 13 | 7 | 6 |
| 4 | 5 | 3 | 2 |
| . | ALL . | IDM/HDM-150 . | MP-151 . |
|---|---|---|---|
| No. patients | 70 | 32 | 38 |
| Age | |||
| Median | 61 | 52 | 67 |
| Range | 34-86 | 35-65 | 35-85 |
| Sex (male:female) | 44:26 | 18:14 | 26:12 |
| M-component | |||
| IgG | 44 | 22 | 22 |
| IgA | 16 | 7 | 9 |
| IgD | 1 | 1 | |
| LCD | 9 | 3 | 6 |
| k:λ | 41:29 | 19:13 | 22:16 |
| Stage: | |||
| II-A | 13 | 5 | 8 |
| III-A | 50 | 25 | 25 |
| III-B | 7 | 2 | 5 |
| Performance status (ECOG) | |||
| 0 | 9 | 4 | 5 |
| 1 | 22 | 9 | 13 |
| 2 | 21 | 9 | 12 |
| 3 | 13 | 7 | 6 |
| 4 | 5 | 3 | 2 |
Abbreviation: LCD, light chain disease.
Patients treated with 2 courses of intravenous intermediate dose melphalan, 70 mg/m2 with an interval of 6 weeks (n = 20) or a single IV high-dose melphalan, 140 mg/m2 (n = 12).
Patients treated with intermittent oral melphalan 0.25 mg/kg/d and prednisone 2 mg/kg/d.